Anti-sense oligodeoxynucleotide to fibrogenic cytokine TGF-.beta. and use thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 4, 1997
Grant Date -
N/A
app pub date -
Dec 28, 1995
filing date -
Jun 15, 1993
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention relates to an anti-sense oligodeoxynucleotide to mRNA for one of major fibrogenic cytokines, TGF-.beta., which is secreted in large quantities in wound portion and then stimulates the fibrinoid degeneration of the tissue. The anti-sense oligodeoxynucleotide according to the present invention is complementarily bound to mRNA of TGF-.beta. to inhibit the genetic expression thereof and thus can inhibit the scarring due to the production of fibrogenic cytokines and the fibrinoid degeneration at the wound portion to treat the wound portion so as to have an appearance substantially identical to the normal tissue. Accordingly, the present invention also relates to the use of anti-sense oligodeoxynucleotide to TGF-.beta. as a scarring inhibitor.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully